Curcumin chemosensitizes 5-fluorouracil resistant MMR-deficient human colon cancer cells in high density cultures

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Shakibaei, Mehdi ^a   Buhrmann, Constanze ^a   Kraehe, Patricia ^a   Shayan, Parviz ^b   Lueders, Cora ^c   Goel, Ajay ^d  

^a UNIVERSITY OF MUNICH   (Germany)

^b Investigating Institute of Molecular Biological System Transfer   (Iran)

^c DEUTSCHES HERZZENTRUM BERLIN   (Germany)

^d BAYLOR RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CURCUMIN; FLUOROURACIL; MISMATCH REPAIR PROTEIN;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER INHIBITION; CANCER STEM CELL; CELL CLONE; COLORECTAL CANCER; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG POTENTIATION; DRUG RESISTANCE; DRUG SENSITIVITY; DRUG SENSITIZATION; HUMAN; HUMAN CELL; MISMATCH REPAIR;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL COUNT; CELL LINE, TUMOR; COLONIC NEOPLASMS; CURCUMIN; DNA MISMATCH REPAIR; DRUG RESISTANCE, NEOPLASM; FLUOROURACIL; HCT116 CELLS; HUMANS; NEOPLASTIC STEM CELLS; SPHEROIDS, CELLULAR; TUMOR CELLS, CULTURED;

EID: 84896793471     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0085397     Document Type: Article

References (57)

1. Jemal A, Center MM, Ward E, Thun MJ (2009) Cancer occurrence. Methods Mol Biol 471: 3-29.
2. Chibaudel B, Tournigand C, Andre T, de Gramont A (2012) Therapeutic strategy in unresectable metastatic colorectal cancer. Ther Adv Med Oncol 4: 75-89.
3. Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63: 11-30.
4. Zhang N, Yin Y, Xu SJ, Chen WS (2008) 5-Fluorouracil: mechanisms of resistance and reversal strategies. Molecules 13: 1551-1569.
5. Shakibaei M, Mobasheri A, Lueders C, Busch F, Shayan P, et al. (2013) Curcumin enhances the effect of chemotherapy against colorectal cancer cells by inhibition of NF-kappaB and Src protein kinase signaling pathways. PLoS One 8: e57218.
6. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100: 57-70. (Pubitemid 30046295)
7. Esteller M (2008) Epigenetics in cancer. N Engl J Med 358: 1148-1159.
8. Drummond JT, Anthoney A, Brown R, Modrich P (1996) Cisplatin and adriamycin resistance are associated with Mut Lalpha and mismatch repair deficiency in an ovarian tumor cell line. J Biol Chem 271: 19645-19648.
9. Kolodner RD, Marsischky GT (1999) Eukaryotic DNA mismatch repair. Curr Opin Genet Dev 9: 89-96. (Pubitemid 29080392)
10. Abdul Khalek FJ, Gallicano GI, Mishra L (2010) Colon cancer stem cells. Gastrointest Cancer Res: S16-23.
11. Boman BM, Wicha MS (2008) Cancer stem cells: a step toward the cure. J Clin Oncol 26: 2795-2799.
12. Dalerba P, Clarke MF (2007) Cancer stem cells and tumor metastasis: first steps into uncharted territory. Cell Stem Cell 1: 241-242. (Pubitemid 47355332)
13. Dick JE (2008) Stem cell concepts renew cancer research. Blood 112: 4793-4807.
14. Jordan CT, Guzman ML, Noble M (2006) Cancer stem cells. N Engl J Med 355: 1253-1261. (Pubitemid 44427449)
15. Vermeulen L, Todaro M, de Sousa Mello F, Sprick MR, Kemper K, et al. (2008) Single-cell cloning of colon cancer stem cells reveals a multi-lineage differentiation capacity. Proc Natl Acad Sci U S A 105: 13427-13432.
16. Huang EH, Hynes MJ, Zhang T, Ginestier C, Dontu G, et al. (2009) Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cells (SC) and tracks SC overpopulation during colon tumorigenesis. Cancer Res 69: 3382-3389.
17. Todaro M, Francipane MG, Medema JP, Stassi G (2010) Colon cancer stem cells: promise of targeted therapy. Gastroenterology 138: 2151-2162.
18. Sung MK, Park MY (2013) Nutritional modulators of ulcerative colitis: Clinical efficacies and mechanistic view. World J Gastroenterol 19: 994-1004.
19. Aggarwal BB (2004) Nuclear factor-kappaB: the enemy within. Cancer Cell 6: 203-208.
20. Bharti AC, Aggarwal BB (2002) Nuclear factor-kappa B and cancer: its role in prevention and therapy. Biochem Pharmacol 64: 883-888. (Pubitemid 35238030)
21. Gupta SC, Kim JH, Prasad S, Aggarwal BB (2010) Regulation of survival, proliferation, invasion, angiogenesis, and metastasis of tumor cells through modulation of inflammatory pathways by nutraceuticals. Cancer Metastasis Rev 29: 405-434.
22. Majumdar AP, Banerjee S, Nautiyal J, Patel BB, Patel V, et al. (2009) Curcumin synergizes with resveratrol to inhibit colon cancer. Nutr Cancer 61: 544-553.
23. Patel BB, Sengupta R, Qazi S, Vachhani H, Yu Y, et al. (2008) Curcumin enhances the effects of 5-fluorouracil and oxaliplatin in mediating growth inhibition of colon cancer cells by modulating EGFR and IGF-1R. Int J Cancer 122: 267-273. (Pubitemid 350234711)
24. Yu Y, Kanwar SS, Patel BB, Nautiyal J, Sarkar FH, et al. (2009) Elimination of Colon Cancer Stem-Like Cells by the Combination of Curcumin and FOLFOX. Transl Oncol 2: 321-328.
25. Bharti AC, Donato N, Singh S, Aggarwal BB (2003) Curcumin (diferuloylmethane) down-regulates the constitutive activation of nuclear factor-kappa B and IkappaBalpha kinase in human multiple myeloma cells, leading to suppression of proliferation and induction of apoptosis. Blood 101: 1053-1062. (Pubitemid 36139379)
26. Duarte VM, Han E, Veena MS, Salvado A, Suh JD, et al. (2010) Curcumin enhances the effect of cisplatin in suppression of head and neck squamous cell carcinoma via inhibition of IKK? protein of the nuclear factor kB pathway. Mol Cancer Ther 9: 2665-2675.
27. Shishodia S, Chaturvedi MM, Aggarwal BB (2007) Role of curcumin in cancer therapy. Curr Probl Cancer 31: 243-305. (Pubitemid 47077491)
28. Chauhan DP (2002) Chemotherapeutic potential of curcumin for colorectal cancer. Curr Pharm Des 8: 1695-1706. (Pubitemid 34846196)
29. Koi M, Umar A, Chauhan DP, Cherian SP, Carethers JM, et al. (1994) Human chromosome 3 corrects mismatch repair deficiency and microsatellite instability and reduces N-methyl-N9-nitro-N-nitrosoguanidine tolerance in colon tumor cells with homozygous hMLH1 mutation. Cancer Res 54: 4308-4312.
30. Csaki C, Keshishzadeh N, Fischer K, Shakibaei M (2008) Regulation of inflammation signalling by resveratrol in human chondrocytes in vitro. Biochem Pharmacol 75: 677-687.
31. Shakibaei M (1998) Inhibition of chondrogenesis by integrin antibody in vitro. Exp Cell Res 240: 95-106. (Pubitemid 28366614)
32. Shakibaei M, De Souza P, Merker HJ (1997) Integrin expression and collagen type II implicated in maintenance of chondrocyte shape in monolayer culture: an immunomorphological study. Cell Biol Int 21: 115-125. (Pubitemid 27122419)
33. Buhrmann C, Mobasheri A, Busch F, Aldinger C, Stahlmann R, et al. (2011) Curcumin modulates nuclear factor kappaB (NF-kappaB)-mediated inflammation in human tenocytes in vitro: role of the phosphatidylinositol 3-kinase/Akt pathway. J Biol Chem 286: 28556-28566.
34. Dallas NA, Xia L, Fan F, Gray MJ, Gaur P, et al. (2009) Chemoresistant colorectal cancer cells, the cancer stem cell phenotype, and increased sensitivity to insulin-like growth factor-I receptor inhibition. Cancer Res 69: 1951-1957.
35. Swindall AF, Stanley JA, Yang ES (2013) PARP-1: Friend or Foe of DNA Damage and Repair in Tumorigenesis? Cancers (Basel) 5: 943-958.
36. Borralho PM, Moreira da Silva IB, Aranha MM, Albuquerque C, Nobre Leitao C, et al. (2007) Inhibition of Fas expression by RNAi modulates 5-fluorouracilinduced apoptosis in HCT116 cells expressing wild-type p53. Biochim Biophys Acta 1772: 40-47. (Pubitemid 44960726)
37. Gonzalez-Vallinas M, Molina S, Vicente G, de la Cueva A, Vargas T, et al. (2013) Antitumor effect of 5-fluorouracil is enhanced by rosemary extract in both drug sensitive and resistant colon cancer cells. Pharmacol Res.
38. Kunkel TA, Erie DA (2005) DNA mismatch repair. Annu Rev Biochem 74: 681-710. (Pubitemid 40995521)
39. Fukui K (2010) DNA mismatch repair in eukaryotes and bacteria. J Nucleic Acids 2010.
40. Fujita H, Kato J, Horii J, Harada K, Hiraoka S, et al. (2007) Decreased expression of hMLH1 correlates with reduced 5-fluorouracil-mediated apoptosis in colon cancer cells. Oncol Rep 18: 1129-1137.
41. Sargent DJ, Marsoni S, Monges G, Thibodeau SN, Labianca R, et al. (2010) Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol 28: 3219-3226.
42. Jiang Z, Jin S, Yalowich JC, Brown KD, Rajasekaran B (2010) The mismatch repair system modulates curcumin sensitivity through induction of DNA strand breaks and activation of G2-M checkpoint. Mol Cancer Ther 9: 558-568.
43. Du B, Jiang L, Xia Q, Zhong L (2006) Synergistic inhibitory effects of curcumin and 5-fluorouracil on the growth of the human colon cancer cell line HT-29. Chemotherapy 52: 23-28. (Pubitemid 43004433)
44. Kanwar SS, Yu Y, Nautiyal J, Patel BB, Padhye S, et al. (2011) Difluorinated curcumin (CDF): a novel curcumin analog is a potent inhibitor of colon cancer stem-like cells. Pharm Res 28: 827-838.
45. Dalerba P, Dylla SJ, Park IK, Liu R, Wang X, et al. (2007) Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci U S A 104: 10158-10163. (Pubitemid 47175279)
46. Stuelten CH, Mertins SD, Busch JI, Gowens M, Scudiero DA, et al. (2010) Complex display of putative tumor stem cell markers in the NCI60 tumor cell line panel. Stem Cells 28: 649-660.
47. Fang D, Nguyen TK, Leishear K, Finko R, Kulp AN, et al. (2005) A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res 65: 9328-9337. (Pubitemid 41508000)
48. Lawson DA, Witte ON (2007) Stem cells in prostate cancer initiation and progression. J Clin Invest 117: 2044-2050. (Pubitemid 47219544)
49. Ali S, Ahmad A, Banerjee S, Padhye S, Dominiak K, et al. (2010) Gemcitabine sensitivity can be induced in pancreatic cancer cells through modulation of miR-200 and miR-21 expression by curcumin or its analogue CDF. Cancer Res 70: 3606-3617.
50. Bao B, Ali S, Banerjee S, Wang Z, Logna F, et al. (2012) Curcumin analogue CDF inhibits pancreatic tumor growth by switching on suppressor microRNAs and attenuating EZH2 expression. Cancer Res 72: 335-345.
51. Polyak K, Hahn WC (2006) Roots and stems: stem cells in cancer. Nat Med 12: 296-300. (Pubitemid 43355075)
52. Dihlmann S, von Knebel Doeberitz M (2005) Wnt/beta-catenin-pathway as a molecular target for future anti-cancer therapeutics. Int J Cancer 113: 515-524. (Pubitemid 40038726)
53. Ali S, Banerjee S, Schaffert JM, El-Rayes BF, Philip PA, et al. (2010) Concurrent inhibition of NF-kappaB, cyclooxygenase-2, and epidermal growth factor receptor leads to greater anti-tumor activity in pancreatic cancer. J Cell Biochem 110: 171-181.
54. Eden S, Cedar H (1994) Role of DNA methylation in the regulation of transcription. Curr Opin Genet Dev 4: 255-259. (Pubitemid 24114857)
55. Tate PH, Bird AP (1993) Effects of DNA methylation on DNA-binding proteins and gene expression. Curr Opin Genet Dev 3: 226-231. (Pubitemid 23108662)
56. Hollenbach JP, Resch AM, Palakodeti D, Graveley BR, Heinen CD (2011) Loss of DNA mismatch repair imparts a selective advantage in planarian adult stem cells. PLoS One 6: e21808.
57. Vaish M (2007) Mismatch repair deficiencies transforming stem cells into cancer stem cells and therapeutic implications. Mol Cancer 6: 26.